CEVEC, MEDAC AND PROVECS MEDICAL ENTER INTO FAR-REACHING ADENOVIRAL VECTOR COLLABORATION IN ONCOLOGY
- Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP®GT technology
- Collaboration is next step in setting CAP®GT as global standard in adenoviral gene therapy
Cologne, Wedel and Hamburg, Germany, March 16, 2017
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications.